NASDAQ$TCMD
Tactile Systems Technology Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Revenue increased but earnings decreased due to various factors including the Delta variant and increased operating expenses.
Tactile Systems Technology reported a 7% increase in revenue for Q3 2021, reaching $52.5 million. However, the company experienced a net loss of $3.4 million, a decrease compared to the net income of $2.4 million in Q3 2020. The results were impacted by COVID-19, the Delta variant, and challenges in the labor market.
- Total revenue increased 7% year-over-year to $52.5 million.
- Operating loss of $1.4 million, compared to operating income of $1.8 million in third quarter 2020.
- Net loss of $3.4 million, compared to net income of $2.4 million in third quarter 2020.
- The company acquired the assets of the AffloVest respiratory therapy business.
Headline financials
Revenue & EPS history
Tactile Systems · Revenue · Quarterly
$52.5M
Revenue by segment
Tactile Systems · $68.3M total across 2 segments · Q2 2023
- Lymphedema products$60M+16.2%87.8%
- Airway clearance products$8.34M+4.1%12.2%
Forward guidance
The Company now expects full year 2021 total revenue in the range of $203.5 million to $206.0 million, representing growth of approximately 9% to 10% year-over-year, compared to total revenue of $187.1 million in 2020. This includes the AffloVest expected revenue range of approximately $5.0 million to $5.5 million from the closing date of September 8, 2021 to December 31, 2021.
Tailwinds
- Expected revenue contribution from AffloVest acquisition of $5.0 to $5.5 million.
- Integration of AffloVest is progressing well.
- Expanded addressable U.S. market opportunity to over $10 billion per year.
- Commitment to advancing the at-home treatment of patients with underserved chronic conditions.
- Expect to deliver strong growth and improving profitability as conditions improve.
Headwinds
- Continued COVID-related headwinds.
- Salesforce staffing challenges.
- Prolonged recovery from COVID-19.
- Resurgence due to the Delta variant during the period, which resulted in restricted access to clinics and hospitals and disrupted the recovery in patient visits versus the pre-COVID environment.
- Challenging labor market impacted our ability to recruit and retain quality candidates for our direct sales force.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+3.1%
Avg return
Earnings day
+3.6%
Avg return
5 days after
+5.9%
Avg return
30 days after
64%
29 / 45 earnings
Positive
+40.6%
Q3 2025
Best reaction
-29.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.2% | +14.5% | +12.2% | |
| Q4 2025 | +17.4% | +2.2% | -7.0% | |
| Q3 2025 | +40.6% | +57.6% | +70.0% | |
| Q1 2025 | -29.0% | -31.6% | -27.5% | |
| Q4 2024 | -13.3% | -16.6% | -25.6% | |
| Q3 2024 | -8.6% | +2.2% | +29.5% | |
| Q2 2024 | +7.2% | +8.6% | +8.4% | |
| Q1 2024 | +1.1% | -2.6% | -15.2% | |
| Q4 2023 | -5.4% | +8.0% | +12.6% | |
| Q3 2023 | -22.8% | -16.9% | +1.3% | |
| Q2 2023 | -14.7% | -10.2% | -10.1% | |
| Q1 2023 | +14.0% | +15.7% | +29.6% | |
| Q4 2022 | +2.4% | +7.6% | +13.5% | |
| Q3 2022 | +17.8% | +27.5% | +49.9% | |
| Q2 2022 | +18.2% | +15.0% | +6.5% | |
| Q1 2022 | +2.4% | -22.9% | -41.8% | |
| Q4 2021 | +7.3% | +29.9% | +30.6% | |
| Q3 2021 | -22.9% | -22.1% | -44.1% | |
| Q2 2021 | -9.1% | -10.8% | -8.6% | |
| Q1 2021 | -7.5% | -2.4% | -9.0% | |
| Q4 2020 | -10.4% | -15.0% | -13.7% | |
| Q3 2020 | +5.4% | -2.7% | +14.4% | |
| Q2 2020 | -13.3% | -8.4% | -9.9% | |
| Q1 2020 | -1.0% | +3.2% | +4.8% | |
| Q4 2019 | -2.8% | -6.3% | -28.2% | |
| Q3 2019 | +7.8% | +12.4% | +35.8% | |
| Q2 2019 | -9.6% | -7.6% | -11.3% | |
| Q1 2019 | +4.5% | +4.0% | -4.6% | |
| Q4 2018 | +0.4% | +2.9% | -27.5% | |
| Q3 2018 | -7.9% | -5.6% | -18.2% | |
| Q2 2018 | +13.4% | +12.4% | +37.6% | |
| Q1 2018 | +20.0% | +26.8% | +41.2% | |
| Q4 2017 | +7.8% | +1.6% | -0.8% | |
| Q3 2017 | -10.4% | -7.6% | -1.1% | |
| Q2 2017 | +17.4% | +7.7% | +19.3% | |
| Q1 2016 | +13.9% | +22.1% | +31.1% | |
| Q1 2017 | +13.9% | +22.1% | +31.1% | |
| Q1 2015 | +17.7% | +10.2% | +6.1% | |
| Q4 2016 | +17.7% | +10.2% | +6.1% | |
| Q4 2014 | +17.7% | +10.2% | +6.1% | |
| Q3 2015 | +7.6% | +2.1% | -11.1% | |
| Q3 2016 | +7.6% | +2.1% | -11.1% | |
| Q4 2015 | +6.8% | +3.9% | +31.8% | |
| Q2 2016 | +6.8% | +3.9% | +31.8% | |
| Q2 2015 | +6.8% | +3.9% | +31.8% | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro